Mr
Rajiv Gandhi
CEO & MD, Hester Biosciences
Having consolidated its
position in the poultry vaccine market, Hester Biosciences has
chartered out mammoth plans in the global animal biologicals market
|
![](/IMG/206/46206/hestergandhi.jpg) |
Hester Biosciences (HBL), Gujarat, has been in the business of
veterinary vaccines for more than a decade and since then it has been
striving towards increasing its product basket and expanding its
geographical reach. Today, its product range includes 39 types of
poultry vaccines. Hester has a state-of-the-art facility to produce
veterinary vaccines. It has the capacity to manufacture over five
billion doses of animal vaccines, with the current capacity utilization
being 35 percent. Apart from export of vaccines, Hester imports one
vaccine from the US. Besides marketing its own vaccines, Hester
represents companies like Merial, US and Biopharm, Czech Republic for
poultry vaccines; and Synbiotics, US for animal diagnostic kits in the
Indian market. Hester achieved a turnover of
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
37.5 crore in the last
financial year, with a PAT of
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
6.03 crore. Throwing light on the
company’s performance during a difficult year for the overall animal
vaccine market, Rajiv Gandhi, CEO and managing director, Hester
Biosciences, says, “Currently, Hester is exporting to 10 countries. In
the financial year 2009-10, our exports were 2.5 percent of our
sales. This year, it is estimated to be over 8 percent of our sales.”
Global Plans
At a time when India is heading towards becoming a vaccine production
hub of the world, Hester visualizes a very bright future for itself in
the animal biological segment. Hester started as a company producing
poultry biological and is now increasing its product range by getting
into large animal biologicals. Its current healthy financial status is
at a time when the company is operating at a 55 percent capacity.
Gandhi predicts that higher capacity utilization will only lead to an
improved bottom line. He says, “Hester aims to have a significant
worldwide presence in the segment of animal biologicals. To achieve
this objective, Hester intends to target Africa, Asia, East Europe and
South America. Presence in these markets would be either through
distributors or by setting up biological manufacturing units in
strategic locations, mainly to overcome the non tariff barriers.”
Gandhi also expects Africa and Asia to be the big growth
areas for animal biologicals. The company aims a turnover of
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
500
crore in the next four years, with 100% of the revenue coming from
animal biologicals.
HBL made its strong footing in Nepal last year by signing a joint
venture agreement with Him Electronics (HEPL), Nepal, to establish an
animal vaccine manufacturing plant in Nepal, a first of its kind in the
country. The proposed company – Hester Biosciences Nepal Private
Limited, would manufacture a range of poultry, sheep, cattle and swine
vaccines for the market in Nepal as well as the global market with an
investment of
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
15 crore. The facility will qualify for WHO GMP
certification, besides getting ISO, EMS, OHSAS accreditation.
To ensure long-term sustenance and to maintain a competitive edge
internationally, Hester intends to invest in a R&D unit in the US.
The proposed R&D center would do applied research to
commercialize the technology in all the production units of Hester,
across the globe.
Nayantara Som in Mumbai